Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
- AAV8 vector containing a novel hybrid promoter selected based on findings of robust, comparative study in mouse model of Pompe disease - Results presented today at 14th Annual WORLDSymposium 2018 - Plan to file AT982 IND in the second quarter of 2018 - Plan to initiate a Phase 1 / 2 clinical
Toggle Summary Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
- AAV8 vector containing a novel hybrid promoter selected based on findings of robust, comparative study in mouse model of Pompe disease - Results presented today at 14th Annual WORLDSymposium 2018 - Plan to file AT982 IND in the second quarter of 2018 - Plan to initiate a Phase 1 / 2 clinical
Toggle Summary Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO , Jan. 29, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the closing of its
Toggle Summary Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO , Jan. 24, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its
Toggle Summary Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO , Jan. 23, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced today that it intends to offer
Toggle Summary Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
- Significant improvements in neuromuscular function as assessed by the CHOP-INTEND scale - Significant improvements in respiratory function as assessed by maximal inspiratory pressure (MIP) - Multiple developmental milestones achieved at 12 weeks in first treated patient SAN FRANCISCO , Jan.
Toggle Summary Audentes Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO , Jan. 3, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.